Volume 21, Number 6—June 2015
Consensus on the Development of Vaccines against Naturally Acquired Melioidosis
|Vaccine characteristics||Vaccines against naturally acquired melioidosis||Melioidosis vaccines for biodefense purposes|
|Character||Persons with diabetes mellitus||Healthy persons|
|Route of exposure
|Potential use of vaccine|
|Prophylaxis plus postexposure antimicrobial drug administration
|Addition of diabetic mouse model||Required||Not required|
|Route of Burkholderia pseudomallei challenge||Subcutaneous||Inhalation|
|Nonhuman primate model||Required||Required|
*Administration of antimicrobial drugs after symptoms occur.
†Administration of antimicrobial drugs after release.
1Group members are listed at the end of this article.
Page created: April 29, 2015
Page updated: April 29, 2015
Page reviewed: April 29, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.